X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80) 80
index medicus (76) 76
female (72) 72
oncology (70) 70
middle aged (64) 64
adult (59) 59
aged (55) 55
breast cancer (49) 49
chemotherapy (45) 45
cancer (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
breast neoplasms - drug therapy (30) 30
male (30) 30
metastasis (27) 27
breast neoplasms - pathology (26) 26
prognosis (26) 26
survival (26) 26
medicine & public health (25) 25
treatment outcome (24) 24
disease-free survival (23) 23
medical colleges (23) 23
therapy (23) 23
neoplasm staging (21) 21
retrospective studies (21) 21
aged, 80 and over (20) 20
care and treatment (20) 20
analysis (18) 18
cancer patients (17) 17
breast neoplasms - mortality (15) 15
adjuvant treatment (14) 14
cancer therapies (14) 14
chemotherapy, adjuvant (14) 14
epidermal growth factor (14) 14
kaplan-meier estimate (14) 14
neoplasm metastasis (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
breast neoplasms - metabolism (13) 13
follow-up studies (13) 13
hematology, oncology and palliative medicine (13) 13
surgery (13) 13
tumors (13) 13
young adult (13) 13
antimitotic agents (12) 12
antineoplastic agents (12) 12
antineoplastic agents - therapeutic use (12) 12
trastuzumab (12) 12
cancer research (11) 11
clinical trials (11) 11
health aspects (11) 11
receptor, erbb-2 - metabolism (11) 11
research (11) 11
survival rate (11) 11
carcinoma (10) 10
combination (10) 10
docetaxel (10) 10
drug therapy (10) 10
expression (10) 10
multivariate analysis (10) 10
original (10) 10
original article (10) 10
product development (10) 10
antibodies, monoclonal, humanized - administration & dosage (9) 9
cell line, tumor (9) 9
metastases (9) 9
oncology, experimental (9) 9
proportional hazards models (9) 9
research article (9) 9
risk factors (9) 9
stomach cancer (9) 9
stomach neoplasms - drug therapy (9) 9
taxoids - administration & dosage (9) 9
adjuvant chemotherapy (8) 8
biomarkers, tumor - metabolism (8) 8
breast neoplasms - genetics (8) 8
drug administration schedule (8) 8
erbb-2 protein (8) 8
fluorouracil (8) 8
fluorouracil - administration & dosage (8) 8
immunohistochemistry (8) 8
medical prognosis (8) 8
medicine, general & internal (8) 8
mutation (8) 8
neoadjuvant therapy (8) 8
neoplasm recurrence, local - pathology (8) 8
phase-ii trial (8) 8
resistance (8) 8
women (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
cytotoxicity (7) 7
doxorubicin (7) 7
estrogen (7) 7
gastric cancer (7) 7
gene amplification (7) 7
lymphatic metastasis (7) 7
medical research (7) 7
patient outcomes (7) 7
patients (7) 7
phase-ii (7) 7
recurrence (7) 7
stomach neoplasms - pathology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Journal Article
Journal Article
Human Pathology, ISSN 0046-8177, 2015, Volume 46, Issue 7, pp. 1027 - 1035
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 85, Issue 1, pp. 201 - 207
Purpose Cetuximab-containing chemotherapy is known to be effective for KRAS wild-type metastatic colorectal cancer; however, it is not clear whether... 
Radiology | Hematology, Oncology and Palliative Medicine | CAPECITABINE | GROWTH-FACTOR RECEPTOR | PRIMARY TUMORS | THERAPY | PLUS IRINOTECAN | INTEGRATION | ONCOLOGY | METASTASES | PTEN | INHIBITORS | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Receptor, Epidermal Growth Factor - genetics | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Rectal Neoplasms - genetics | Adult | Female | Rectal Neoplasms - pathology | Cetuximab | Camptothecin - analogs & derivatives | Genes, ras - genetics | Radiotherapy Dosage | Chemoradiotherapy - methods | Camptothecin - therapeutic use | Drug Administration Schedule | Fluorouracil - analogs & derivatives | PTEN Phosphohydrolase - metabolism | Treatment Outcome | Mutation - genetics | Rectal Neoplasms - therapy | Preoperative Care | Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Rectal Neoplasms - metabolism | Deoxycytidine - analogs & derivatives | Medical colleges | Patient outcomes | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Antimitotic agents | Chemotherapy | Genetic aspects | Product development | Cancer | GROWTH FACTORS | PATIENTS | NEOPLASMS | RECTUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | MUTATIONS | RADIOTHERAPY | RECEPTORS | CHEMOTHERAPY
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 25 - 32
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 791 - 800
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1225 - 1233
Journal Article